CONTX-avtale med to kreftsentre i USA, klinisk evaluering INIFY
Endelig skjer det noe i CONTX!
ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate
STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.
Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.
INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.
“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,” says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.
“At Tufts Medical Center, we are in the process of digitalizing pathology,” says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. ”Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”
“We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit cancer.osu.edu.
Tufts Medical Center is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children’s Hospital. Tufts MC’s renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.
ContextVision announces agreement with two renowned US cancer centers for clinical evaluation of INIFY® Prostate
STOCKHOLM – July 6, 2021 – ContextVision, a medical technology software company specializing in image processing, image analysis and decision support tools for digital pathology, today announced that agreements to conduct a multicenter clinical study of ContextVision’s digital pathology product INIFY® Prostate have been signed with the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) in Columbus, OH, and with Tufts Medical Center (Tufts MC), Boston, MA.
Principal investigators for the study are Professor Anil Parwani, M.D., Ph.D., M.B.A at OSUCCC – James and Ming Zhou, MD, PhD, Chair and Pathologist-in-Chief at Tufts MC. The study will evaluate how INIFY Prostate can improve the performance of resident diagnosis when reviewing prostate biopsy samples. Ground truth will be provided by the two principal investigators, world-renowned sub-specialists within prostate cancer.
INIFY is a powerful AI-based software that precisely outlines suspected cancerous areas in prostate biopsies, with unique, detailed pixel-level focus. Based on a patented annotation method used in training of the algorithms – MasterAnnotation – INIFY pre-sorts slides in a worst-first order, and comes with a user-friendly viewer designed for handling prostate biopsies.
“As president of the Digital Pathology Association and one of few sites in the US being fully digitalized, I’m eager to explore how the use of AI-based decision support tools can support prostate diagnosis, and potentially improve workflow,” says Anil Parwani, Director of Pathology Informatics and Director of the Digital Pathology Shared Resource at OSUCCC – James.
“At Tufts Medical Center, we are in the process of digitalizing pathology,” says Dr. Zhou, Chair and Pathologist-in-Chief at Tufts MC. ”Our department certainly would benefit from a tool to support high quality diagnosis and speed up this transition.”
“We are very excited and proud to have the opportunity to cooperate with two of the most respected pathologists within the society, and their clinics, for driving the digitalization process,” says Magnus Aurell, VP Business Unit Digital Pathology at ContextVision.
The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute strives to create a cancer-free world by integrating scientific research with excellence in education and patient-centered care, a strategy that leads to better methods of prevention, detection and treatment. Ohio State is one of only 51 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers. As the cancer program’s 356-bed adult patient-care component, The James is one of the top cancer hospitals in the nation as ranked by U.S. News & World Report and has achieved Magnet designation, the highest honor an organization can receive for quality patient care and professional nursing practice. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical cancer care. To learn more, visit cancer.osu.edu.
Tufts Medical Center is an exceptional, not-for-profit, 415 bed academic medical center that is home to both a full-service hospital for adults and Tufts Children’s Hospital. Tufts MC’s renowned research program ranks among the top 10 percent of independent hospitals to receive federal research funding. The Medical Center is the principle teaching hospital for Tufts University School of Medicine. The Department of Pathology and Laboratory Medicine includes more than 200 dedicated pathologists, medical technologists, medical technicians, phlebotomists and administrative staff who provide comprehensive diagnostic testing services in a wide variety of areas within anatomic and clinical pathology. The faculty members are engaged in cutting edge research that aims to translate bench research to bedside patient care.
kreinh
06.07.2021 kl 11:43
1800
focuss, har du sett komentaren min til deg i går på tråden: RE: Blåruss og Vekst vs verdiaksjer.
focuss
06.07.2021 kl 12:01
1777
kreinh
Ja jeg så den. Har vært heldig med denne tidligere og va med fra ca 75 til over 200 før den ble splittet 1:10 Digital Patologi virker jo som det er et åpenbart behov for. Må si jeg ble overasket over at de nå slipper til i USA. De bør kunne ta seg bedre betalt der kanskje, men først skal det testes. Det er jeg overbevist om at blir suksess.
Ja jeg så den. Har vært heldig med denne tidligere og va med fra ca 75 til over 200 før den ble splittet 1:10 Digital Patologi virker jo som det er et åpenbart behov for. Må si jeg ble overasket over at de nå slipper til i USA. De bør kunne ta seg bedre betalt der kanskje, men først skal det testes. Det er jeg overbevist om at blir suksess.
focuss
06.07.2021 kl 12:15
1757
Synes godt de kunne børsmeldt dette. Det er klart at det å slippe til i USA øker aksjens potensiale/verdi.
bulleye
06.07.2021 kl 12:21
1740
Jeg har sendt en epost til CEO og CFO allerede kl. 9.30 og spurte om hvorfor denne ikke var børsmeldt. I det minste burde den legges ut på hjemmesiden.
Nevnte samtidig at CONTX siste børsmelding var angående GF tidlig i mai og at vi aksjonærer nå er "sulteforet" på nyheter fra selskapet om hvordan fremdriften angående digital patologi.
Nevnte samtidig at CONTX siste børsmelding var angående GF tidlig i mai og at vi aksjonærer nå er "sulteforet" på nyheter fra selskapet om hvordan fremdriften angående digital patologi.
Redigert 06.07.2021 kl 12:22
Du må logge inn for å svare
kreinh
06.07.2021 kl 12:50
1703
Godt initiativ bulleye. Dette er ikke ett selskap som må hausse og holde oppmerksomheten oppe slik andre selskap gjør som lever av emisjoner. ;-)
Men helt taus trenger de ikke å være....
Men helt taus trenger de ikke å være....
bulleye
08.07.2021 kl 11:22
1458
Har ikke mottatt svar ennå, men ser på hjemmesiden at meldingen er lagt ut etter min purring.
Det er da i allefall noe..
Det er da i allefall noe..
bulleye
18.10.2021 kl 12:08
962
INIFY Prostate® shown to accurately outline
suspicious prostate cancer in study with two
prominent medical centers
STOCKHOLM – October 18, 2021 – ContextVision, a medical technology software company
specializing in image processing, image analysis and decision support tools for digital
pathology, today announced that results from a US clinical evaluation were presented at the
Pathology Visions Congress in Las Vegas, USA.
The evaluation was performed together with two independent pathologists, Anil Parwani,
M.D., Ph.D., M.B.A. at Ohio State University Comprehensive Cancer Center (Columbus,
Ohio), and Ming Zhou, M.D., Ph.D., Chair and Pathologist-in-Chief at Tufts Medical Center
(Boston, Massachusetts). It showed that for images with small focus of cancer (≤1 mm), the
INIFY algorithm identified all cancer glands and did not miss any. The sensitivity was 100%
in these cases. Also, for images with larger cancer areas, outlining was very precise, with a
sensitivity of 99.3 – 99.8%. For a decision support tool to be an effective companion in the
clinical workflow, it is important that it does not identify too many false positives. In this
evaluation, INIFY Prostate showed a high specificity of 96 – 98%.
“Many pathologists find signing out benign cases to be accompanied by the anxiety of having
missed something important. Decision support tools that are reliable in finding even the
smallest cancer foci can play an important role in increasing diagnostic confidence,” says Dr.
Zhou.
Prostate biopsy slides from 30 unique patients from both Wexner and Tufts medical centers
were scanned using three different scanners. Drs. Parwani and Zhou reviewed INIFY
Prostate’s predictions of suspicious cancer areas in all scanned slides. The aim of the
evaluation was to see whether the product’s performance differed depending on pathology
lab (i.e., variations in slide preparation such as staining) or scanners used. It was concluded
that INIFY Prostate works equally well on images from both labs, rendering very similar
outcomes in terms of sensitivity and specificity. Thus, the INIFY predictions are robust.
“This is the first quality assurance study that has compared the performance of a prostate
algorithm on images scanned on three different scanners side by side,” says Dr. Parwani.
INIFY is a powerful AI-based software that precisely outlines suspicious cancer areas in
prostate biopsies, with unique, detailed pixel-level focus – a result of MasterAnnotation, a
patented annotation method used in training of the algorithms.
“This result adds to several studies that confirms INIFY’s ability to support the pathologists in
their daily clinical work,” says Magnus Aurell, VP Business Unit Digital Pathology at
ContextVision.
###
For further information, please contact ContextVision’s CEO, Fredrik Palm, at
suspicious prostate cancer in study with two
prominent medical centers
STOCKHOLM – October 18, 2021 – ContextVision, a medical technology software company
specializing in image processing, image analysis and decision support tools for digital
pathology, today announced that results from a US clinical evaluation were presented at the
Pathology Visions Congress in Las Vegas, USA.
The evaluation was performed together with two independent pathologists, Anil Parwani,
M.D., Ph.D., M.B.A. at Ohio State University Comprehensive Cancer Center (Columbus,
Ohio), and Ming Zhou, M.D., Ph.D., Chair and Pathologist-in-Chief at Tufts Medical Center
(Boston, Massachusetts). It showed that for images with small focus of cancer (≤1 mm), the
INIFY algorithm identified all cancer glands and did not miss any. The sensitivity was 100%
in these cases. Also, for images with larger cancer areas, outlining was very precise, with a
sensitivity of 99.3 – 99.8%. For a decision support tool to be an effective companion in the
clinical workflow, it is important that it does not identify too many false positives. In this
evaluation, INIFY Prostate showed a high specificity of 96 – 98%.
“Many pathologists find signing out benign cases to be accompanied by the anxiety of having
missed something important. Decision support tools that are reliable in finding even the
smallest cancer foci can play an important role in increasing diagnostic confidence,” says Dr.
Zhou.
Prostate biopsy slides from 30 unique patients from both Wexner and Tufts medical centers
were scanned using three different scanners. Drs. Parwani and Zhou reviewed INIFY
Prostate’s predictions of suspicious cancer areas in all scanned slides. The aim of the
evaluation was to see whether the product’s performance differed depending on pathology
lab (i.e., variations in slide preparation such as staining) or scanners used. It was concluded
that INIFY Prostate works equally well on images from both labs, rendering very similar
outcomes in terms of sensitivity and specificity. Thus, the INIFY predictions are robust.
“This is the first quality assurance study that has compared the performance of a prostate
algorithm on images scanned on three different scanners side by side,” says Dr. Parwani.
INIFY is a powerful AI-based software that precisely outlines suspicious cancer areas in
prostate biopsies, with unique, detailed pixel-level focus – a result of MasterAnnotation, a
patented annotation method used in training of the algorithms.
“This result adds to several studies that confirms INIFY’s ability to support the pathologists in
their daily clinical work,” says Magnus Aurell, VP Business Unit Digital Pathology at
ContextVision.
###
For further information, please contact ContextVision’s CEO, Fredrik Palm, at
bulleye
18.10.2021 kl 12:12
957
Norsk versjon av børsmelding angående INIFY.
Dette viser at CONTX har utvilket et meget presist og nøyaktig verktøy som kan revolusjonere og radikalt endre hvordan ulike kreftformer blir påvist.
Nå bør alt være klart for at endelige kontrakter kan inngås.
INIFY Prostate® viste å nøyaktig skissere mistenkelig prostatakreft i studier med to fremtredende medisinske sentre
STOCKHOLM - 18. oktober 2021 - ContextVision, et medisinsk teknologiselskap som spesialiserer seg på bildebehandling, bildeanalyse og beslutningsstøtteverktøy for digital patologi, kunngjorde i dag at resultater fra en amerikansk klinisk evaluering ble presentert på Pathology Visions Congress i Las Vegas, USA . Evalueringen ble utført sammen med to uavhengige patologer, Anil Parwani, MD, Ph.D., MBA ved Ohio State University Comprehensive Cancer Center (Columbus, Ohio) og Ming Zhou, MD, Ph.D., Chair and Pathologist-in - Sjef ved Tufts Medical Center (Boston, Massachusetts). Den viste at for bilder med lite kreftfokus (<= 1 mm), identifiserte INIFY -algoritmen alle kreftkjertlene og savnet ingen. Følsomheten var 100% i disse tilfellene. For bilder med større kreftområder var oversikten veldig presis, med en sensitivitet på 99,3 - 99,8%. For at et beslutningsstøtteverktøy skal være en effektiv ledsager i den kliniske arbeidsflyten, er det viktig at det ikke identifiserer for mange falske positiver. I denne evalueringen viste INIFY Prostate en høy spesifisitet på 96 - 98%. "Mange patologer synes å melde seg ut godartede tilfeller ledsaget av angst for å ha gått glipp av noe viktig. Beslutningsstøtteverktøy som er pålitelige for å finne selv de minste kreftfokusene kan spille en viktig rolle for å øke diagnostisk tillit," sier Dr. Zhou. Prostatabiopsidia fra 30 unike pasienter fra både Wexner og Tufts medisinske sentre ble skannet ved hjelp av tre forskjellige skannere. Drs. Parwani og Zhou gjennomgikk INIFY Prostates spådommer om mistenkelige kreftområder i alle skannede lysbilder. Målet med evalueringen var å se om produktets ytelse var forskjellig avhengig av patologilaboratorium (dvs. variasjoner i objektglassforberedelse som farging) eller skannere som ble brukt. Det ble konkludert med at INIFY Prostate fungerer like godt på bilder fra begge laboratoriene, noe som gir svært like resultater når det gjelder sensitivitet og spesifisitet. Dermed er INIFY -spådommene robuste. "Dette er den første kvalitetssikringsstudien som har sammenlignet ytelsen til en prostata -algoritme på bilder skannet på tre forskjellige skannere side om side," sier Dr. Parwani. INIFY er en kraftig AI-basert programvare som presist skisserer mistenkelige kreftområder i prostatabiopsier, med unikt, detaljert pikselnivåfokus-et resultat av MasterAnnotation, en patentert merkingsmetode som brukes i trening av algoritmene. " Vår ekspertise er å utvikle kraftige programvareprodukter, basert på proprietær teknologi og kunstig intelligens for bildebaserte applikasjoner. Vår banebrytende teknologi hjelper klinikere med å tolke medisinske bilder nøyaktig, et avgjørende grunnlag for bedre diagnose og behandling. ContextVision går nå inn i det raskt voksende markedet for digital patologi. Vi investerer betydelig i produktporteføljen vår for beslutningsstøtteverktøy, og vi er opptatt av å bli en ledende ressurs for patologer for å radikalt utvikle kreftdiagnose og forbedre pasientbehandlingen. Selskapet, etablert i 1983, er basert i Sverige med lokal representasjon i USA, Japan, Kina og Korea. ContextVision er notert på Oslo Børs under tickeren CONTX.
Dette viser at CONTX har utvilket et meget presist og nøyaktig verktøy som kan revolusjonere og radikalt endre hvordan ulike kreftformer blir påvist.
Nå bør alt være klart for at endelige kontrakter kan inngås.
INIFY Prostate® viste å nøyaktig skissere mistenkelig prostatakreft i studier med to fremtredende medisinske sentre
STOCKHOLM - 18. oktober 2021 - ContextVision, et medisinsk teknologiselskap som spesialiserer seg på bildebehandling, bildeanalyse og beslutningsstøtteverktøy for digital patologi, kunngjorde i dag at resultater fra en amerikansk klinisk evaluering ble presentert på Pathology Visions Congress i Las Vegas, USA . Evalueringen ble utført sammen med to uavhengige patologer, Anil Parwani, MD, Ph.D., MBA ved Ohio State University Comprehensive Cancer Center (Columbus, Ohio) og Ming Zhou, MD, Ph.D., Chair and Pathologist-in - Sjef ved Tufts Medical Center (Boston, Massachusetts). Den viste at for bilder med lite kreftfokus (<= 1 mm), identifiserte INIFY -algoritmen alle kreftkjertlene og savnet ingen. Følsomheten var 100% i disse tilfellene. For bilder med større kreftområder var oversikten veldig presis, med en sensitivitet på 99,3 - 99,8%. For at et beslutningsstøtteverktøy skal være en effektiv ledsager i den kliniske arbeidsflyten, er det viktig at det ikke identifiserer for mange falske positiver. I denne evalueringen viste INIFY Prostate en høy spesifisitet på 96 - 98%. "Mange patologer synes å melde seg ut godartede tilfeller ledsaget av angst for å ha gått glipp av noe viktig. Beslutningsstøtteverktøy som er pålitelige for å finne selv de minste kreftfokusene kan spille en viktig rolle for å øke diagnostisk tillit," sier Dr. Zhou. Prostatabiopsidia fra 30 unike pasienter fra både Wexner og Tufts medisinske sentre ble skannet ved hjelp av tre forskjellige skannere. Drs. Parwani og Zhou gjennomgikk INIFY Prostates spådommer om mistenkelige kreftområder i alle skannede lysbilder. Målet med evalueringen var å se om produktets ytelse var forskjellig avhengig av patologilaboratorium (dvs. variasjoner i objektglassforberedelse som farging) eller skannere som ble brukt. Det ble konkludert med at INIFY Prostate fungerer like godt på bilder fra begge laboratoriene, noe som gir svært like resultater når det gjelder sensitivitet og spesifisitet. Dermed er INIFY -spådommene robuste. "Dette er den første kvalitetssikringsstudien som har sammenlignet ytelsen til en prostata -algoritme på bilder skannet på tre forskjellige skannere side om side," sier Dr. Parwani. INIFY er en kraftig AI-basert programvare som presist skisserer mistenkelige kreftområder i prostatabiopsier, med unikt, detaljert pikselnivåfokus-et resultat av MasterAnnotation, en patentert merkingsmetode som brukes i trening av algoritmene. " Vår ekspertise er å utvikle kraftige programvareprodukter, basert på proprietær teknologi og kunstig intelligens for bildebaserte applikasjoner. Vår banebrytende teknologi hjelper klinikere med å tolke medisinske bilder nøyaktig, et avgjørende grunnlag for bedre diagnose og behandling. ContextVision går nå inn i det raskt voksende markedet for digital patologi. Vi investerer betydelig i produktporteføljen vår for beslutningsstøtteverktøy, og vi er opptatt av å bli en ledende ressurs for patologer for å radikalt utvikle kreftdiagnose og forbedre pasientbehandlingen. Selskapet, etablert i 1983, er basert i Sverige med lokal representasjon i USA, Japan, Kina og Korea. ContextVision er notert på Oslo Børs under tickeren CONTX.